CommercialCoverageMedium impact
08.00.66w, Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
IBX Commercial plans updated their policy for Bevacizumab (Avastin®) and related biosimilars for oncologic use. This is a reissue of an existing policy with an effective date of 11/26/2025, likely updating coverage criteria or administrative requirements for cancer treatment medications.
Action Required
By November 26, 2025: Billing team should review the full policy details at the provided URL to understand any changes to prior authorization requirements, coverage criteria, or billing procedures for Bevacizumab (Avastin®) and biosimilar medications used in oncology treatment. Update billing system and staff training as needed based on the complete policy content.